Prevalence of low bone mass and vitamin d deficiency in β-thalassemia major

Hemoglobin

Volumn 38, Issue 3, 2014, Pages 173-178

  Tzoulis, Ploutarchos ^a,b   Ang, Ai Leen ^a   Shah, Farrukh T ^a   Berovic, Marko ^b   Prescott, Emma ^a   Jones, Romilla ^a   Barnard, Maria ^a  

^a Department of Diabetes and Endocrinology ^*  (United States)

^b WHITTINGTON HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Complications; Low bone mass; Osteoporosis; Vitamin D; Thalassemia

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM PHOSPHATE; PARATHYROID HORMONE;

ADULT; ARTICLE; BETA THALASSEMIA; BONE DENSITY; BONE MASS; BONE METABOLISM; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; GLYCEMIC INDEX; HUMAN; HYPOGONADISM; IRON OVERLOAD; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; VITAMIN D DEFICIENCY; COMPARATIVE STUDY; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; BETA-THALASSEMIA; BONE DENSITY; FEMALE; HUMANS; HYPOGONADISM; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VITAMIN D DEFICIENCY;

EID: 84900489669     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2014.905792     Document Type: Article

References (41)

1. Jensen CE, Tuck SM, Agnew JE, et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol. 1998;103(4):911-915.
2. Pollak RD, Rachmilewitz E, Blumenfeld A, et al. Bone mineral metabolism in adults with b-thalassaemia major and intermedia. Br J Haematol. 2000;111(3):902-907.
3. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006; 367(9527):2010-2018.
4. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with b thalassaemia. Br J Haematol. 2004;127(2):127-139.
5. Anapliotou M, Kastanias I, Psara P, et al. The contribution of hypogonadism to the development of osteoporosis in thalassemia major: New therapeutic approaches. Clin Endocrinol. 1995; 42(3):279-287.
6. Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassemic patients with transfusion iron overload. Clin Endocrinol. 2000;53(1):33-42.
7. Scacchi M, Danes L, Cattaneio A, et al. Bone demineralization in adult thalassemic patients: contribution of GH and IGF-1 at different skeletal sites. Clin Endocrinol. 2008;69(2):202-207.
8. Lasco A, Morabito N, Gaudio A, et al. Osteoporosis and b-thalassemia major: Role of the IGF-I/IGFBP-III axis. J Endocrinol Invest. 2002;25(4):338-344.
9. Toumba M, Skordis N. Osteoporosis syndrome in thalassemia major: An overview. J Osteoporos. 2010;2010:537673.
10. Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev. 2008; 6(1):86-93.
11. Skordis N, Efstathiou E, Kyriakou A, Toumba M. Hormonal dysregulation and bones in thalassemia-an overview. Pediatr Endocrinol Rev. 2008;6(Suppl 1):107-115.
12. De Sanctis V, Pinamonti A, Di Palma A, et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Paediatr. 1996; 155(5):368-372.
13. Borgna-Pignatti C, Rugolotto S, De Stefan P, et al. Survival and complications in patients with thalasaaemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89(10):1187-1193.
14. Terpos E, Voskaridou E. Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci. 2010;1202:237-243.
15. Johanson NA. Musculoskeletal problems in hemoglobinopathy. Orthop Clin North Am. 1990;21(1):191-198.
16. Origa R, Fiumana E, Gamberini MR, et al. Osteoporosis in b-thalassemia: Clinical and genetic aspects. Ann N Y Acad Sci. 2005;1054:451-456.
17. Wonke B. Bone disease in b-thalassaemia major. Br J Haematol. 1998;103(4):897-901.
18. Tsitura S, Amarilio N, Lapatsanis P, et al. Serum 25-hydroxyvitamin D levels in thalassaemia. Arch Dis Child. 1978;53(4):347-348.
19. Napoli N, Carmina E, Bucchieri S, et al. Low serum levels of 25- hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone. 2006;38(6):888-892.
20. Soliman A, Adel A, Wagdy M, et al. Calcium homeostasis in 40 adolescents with b-thalassemia major: A case-control study of the effects of intramuscular injection of a megadose of cholecalciferol. Pediatr Endocrinol Rev. 2008;6(Suppl 1):149-154.
21. Singh K, Kumar R, Shukla A, et al. Status of 25-hydroxyvitamin D deficiency and effect of vitamin D receptor gene polymorphisms on bone mineral density in thalassemia patients of North India. Hematology. 2012;17(5):291-296.
22. Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Thalassemia Clinical Research Network. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol. 2009; 146(5):546-556.
23. Dandona P, Menon RK, Houlder S, et al. Serum 1,25 dihydroxyvitamin D and osteocalcin concentrations in thalassaemia major. Arch Dis Child. 1987;62(5):474-477.
24. Zaino EC, Yeh JK, Aloia J. Defective vitamin D metabolism in thalassemia major. Ann N Y Acad Sci. 1985;445:127-134.
25. Voskaridou E, Kyrtsonis MC, Terpos E, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol. 2001;112(1):36-41.
26. Moulas A, Challa A, Chaliasos N, Lapatsanis PD. Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in b-thalassaemia. Acta Paediatr. 1997;86(6):594-599.
27. St. Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861.
28. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26(11):3160-3167.
29. World Health Organization Scientific Group on the Prevention and Management of Osteoporosis (2000: Geneva, Switzerland) (2003). Prevention and management of osteoporosis: Report of a WHO scientific group. Accessed September 20 2013.
30. The International Society for Clinical Densitometry. ISCD 2007 official positions-adult. Available at http://www.iscd.org/officialpositions/ 2007-iscd-official-positions-adult/. Accessed September 20 2013.
31. Guidelines for the clinical management of thalassaemia. Thalassaemia International Federation, 2nd ed. 2008:1-202. Available at http://www. thalassaemia.org.cy. Accessed September 20 2013.
32. Standards for the clinical care of children and adults with thalassaemia in the United Kingdom. Thalassaemia Society, 2nd ed. 2008:1-120. Available at http://www.ukts.org. Accessed September 20 2013.
33. Mirhosseini NZ, Shahar S, Ghayour-Mobarhan M, et al. Bonerelated complications of transfusion-dependent b thalassemia among children and adolescents. J Bone Miner Metab. 2013; 31(4):468-476.
34. Wong P, Fuller PJ, Gillespie MT, et al. Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int. 2013;24(7):1965-1971.
35. Vogiatzi MG, Macklin EA, Fung EB, et al. Thalassemia Clinical Research Network. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009; 24(3):543-557.
36. Skordis N, Michaelidou M, Savva SC, et al. The impact of genotype on endocrine complications in thalassaemia major. Eur J Haematol. 2006;77(2):150-156.
37. Bielinski BK, Darbyshire PJ, Mathers L, et al. Impact of disordered puberty on bone density in b-thalassaemia major. Br J Haematol. 2003;120(2):353-358.
38. Rioja L, Girot R, Garabédian M, Cournot-Witmer G. Bone disease in children with homozygous b-thalassemia. Bone Miner. 1990; 8(1):69-86.
39. Kyriakou A, Savva SC, Savvides I, et al. Gender differences in the prevalence and severity of bone disease in thalassemia. Pediatr Endocrinol Rev. 2008; 6(Suppl 1):116-122.
40. Garofalo F, Piga A, Lala R, et al. Bone metabolism in thalassemia. Ann N Y Acad Sci. 1998;850:475-478.
41. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: Nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr. 2007;85(3):860-868.